National Pension Service Sells 24,599 Shares of Eli Lilly And Co (NYSE:LLY)

National Pension Service lessened its position in shares of Eli Lilly And Co (NYSE:LLY) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,036,543 shares of the company’s stock after selling 24,599 shares during the quarter. National Pension Service’s holdings in Eli Lilly And Co were worth $136,233,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $8,141,000. Voya Investment Management LLC raised its holdings in Eli Lilly And Co by 19.3% in the 3rd quarter. Voya Investment Management LLC now owns 2,291,407 shares of the company’s stock valued at $256,249,000 after buying an additional 369,936 shares during the last quarter. Voya Financial Advisors Inc. raised its holdings in Eli Lilly And Co by 14.4% in the 3rd quarter. Voya Financial Advisors Inc. now owns 13,059 shares of the company’s stock valued at $1,467,000 after buying an additional 1,640 shares during the last quarter. Redpoint Investment Management Pty Ltd raised its holdings in Eli Lilly And Co by 1.2% in the 3rd quarter. Redpoint Investment Management Pty Ltd now owns 68,144 shares of the company’s stock valued at $7,621,000 after buying an additional 825 shares during the last quarter. Finally, Lowe Brockenbrough & Co. Inc. raised its holdings in Eli Lilly And Co by 3.0% in the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 10,295 shares of the company’s stock valued at $1,151,000 after buying an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Argus upped their price target on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, December 30th. JPMorgan Chase & Co. raised their price objective on Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Barclays started coverage on Eli Lilly And Co in a research note on Thursday, February 27th. They issued an “overweight” rating on the stock. Goldman Sachs Group raised Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price objective on the stock in a research note on Wednesday, March 11th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $156.00 price objective on shares of Eli Lilly And Co in a research note on Tuesday, February 18th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $142.18.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 32,645 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $132.90, for a total transaction of $4,338,520.50. Following the completion of the transaction, the insider now owns 114,527,954 shares of the company’s stock, valued at $15,220,765,086.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the completion of the sale, the senior vice president now directly owns 44,773 shares of the company’s stock, valued at approximately $6,274,935.95. The disclosure for this sale can be found here. Insiders have sold a total of 682,645 shares of company stock worth $95,516,671 in the last three months. 0.11% of the stock is owned by corporate insiders.

LLY traded down $0.24 on Friday, hitting $134.11. 4,717,376 shares of the company’s stock traded hands, compared to its average volume of 4,785,771. The company’s 50 day simple moving average is $136.58 and its 200-day simple moving average is $124.91. The firm has a market cap of $116.70 billion, a price-to-earnings ratio of 15.31, a P/E/G ratio of 1.52 and a beta of 0.34. Eli Lilly And Co has a one year low of $101.36 and a one year high of $147.87. The company has a current ratio of 1.16, a quick ratio of 0.89 and a debt-to-equity ratio of 5.30.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Thursday, January 30th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.21. The company had revenue of $6.11 billion for the quarter, compared to the consensus estimate of $5.92 billion. Eli Lilly And Co had a return on equity of 192.27% and a net margin of 37.27%. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned $1.33 EPS. As a group, equities analysts anticipate that Eli Lilly And Co will post 6.77 EPS for the current fiscal year.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What strategies should day traders use to execute a trade?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.